Pradžia › Leukemija › Ilinoisas › Chicago
Leukemija klinikiniai tyrimai Chicago, IL
16 tyrimai dėl Leukemija ieško dalyvių vietose Chicago ir aplinkui (apytiksliai 30 mylių spinduliu). Atidarykite tyrimą, kad pamatytumėte, kas gali dalyvauti ir kaip susisiekti su tyrimo komanda.
Oficialus tyrimo tekstas (anglų kalba)
Ieškote dalyvių tyrimui? Pateikite jį šio puslapio viršuje – $99 už 30 dienų →
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Renkami dalyviai1/2 fazė
- The University of Chicago Medical Center, Chicago
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Renkami dalyviai3 fazė
- Research Site, Chicago
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Renkami dalyviai1/2 fazė
- University of Chicago, Chicago
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Renkami dalyviai1 fazė
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Renkami dalyviai2 fazė
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Renkami dalyviai1/2 fazė
- Research Site, Chicago
Mosaic Trial for Stem Cell Transplant Recipients
Renkami dalyviai
- Northwestern University Feinberg School of Medicine, Chicago
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
Renkami dalyviai2 fazė
- University of Chicago Medical Center, Chicago
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Renkami dalyviaiStebimasis tyrimas
- Lurie Children's Hospital-Chicago, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Renkami dalyviai1/2 fazė
- University of Illinois at Chicago Cancer Center, Chicago
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Renkami dalyviai1 fazė
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia
Renkami dalyviai
- UChicago Medicine Comprehensive Cancer Center, Chicago
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
Renkami dalyviai1/2 fazė
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Renkami dalyviai
- University of Chicago Comprehensive Cancer Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Renkami dalyviaiStebimasis tyrimas
- Massive Bio SYNERGY-AI site, Chicago
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Renkami dalyviai1 fazė
- Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Leukemija tyrimai kituose miestuose
- Houston, TX28 tyrimai
- Boston, MA25 tyrimai
- New York City, NY19 tyrimai
- Los Angeles, CA16 tyrimai
- Durham, NC13 tyrimai
- Nashville, TN12 tyrimai
- Baldwin Park, CA12 tyrimai
- Columbus, OH12 tyrimai
- Philadelphia, PA12 tyrimai
- Milwaukee, WI11 tyrimai
- Atlanta, GA11 tyrimai
- Seattle, WA11 tyrimai
Kiti tyrimai Chicago
- Nedidelinių ląstelių plaučių vėžys61 tyrimas
- Krūties vėžys58 tyrimai
- Vėžys (visų tipų)51 tyrimas
- Metastatinis vėžys45 tyrimai
- Prostatos vėžys45 tyrimai
- Nutukimas41 tyrimas
- Plaučių vėžys41 tyrimas
- Kiaušidžių vėžys36 tyrimai
- Insultas34 tyrimai
- Storosios ir tiesiosios žarnos vėžys33 tyrimai
- Širdies nepakankamumas31 tyrimas
- Antsvoris28 tyrimai
Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.